Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

EMPA-REG OUTCOME: Empagliflozin cut insulin need in type 2 diabetes

Publish date:: June 13, 2020

Key clinical point: Treatment of patients with type 2 diabetes with empagliflozin reduced their need to start on insulin or intensify an existing insulin regimen.

Major finding: Patients on empagliflozin had a 60% relative cut in insulin initiation and a 58% relative cut in insulin intensification compared with controls.

Study details: Post-hoc analysis of data from the EMPA-REG OUTCOME trial, with 7,020 patients with type 2 diabetes.

Disclosures: EMPA-REG OUTCOME was funded in part by Boehringer Ingelheim and Eli Lilly, the companies that market empagliflozin (Jardiance). Dr. Vaduganathan has been an advisor to Boehringer Ingelheim and to Amgen, AstraZeneca, Baxter, Bayer, Cytokinetics, and Relypsa.

Citation:

Vaduganathan M. ADA 2020, Abstract 30-OR.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Diabetes

Sac/val heart failure benefit extends to diabetes patients,

Don’t miss cardiovascular risk factors in transgender patients,

Semaglutide shows promise in NASH phase 2 study,

Substance in tears could be used for diabetes monitoring,

Empagliflozin cut PA pressures in heart failure patients,